19 research outputs found
PALINOLOGÍA DEL CUATERNARIO RECIENTE EN LA LAGUNA DE VILLENA (ALICANTE, ESPAÑA)
We present pollen analysis of late Quaternary endorheic deposits at Villena (Alicante, España). Vegetational developments are discussed in the light of climatic, historical, and edaphic determinisms, and within the context of former research in the region and the Mediterranean Basin.Se presentan los resultados del análisis polínico de un depósito endorreico del Cuaternario reciente en las proximidades de Villena (Alicante, España). Se discute la dinámica vegetal en virtud de condicionamientos
climáticos, históricos y edáficos y en el contexto de otros estudios precedentes en el ámbito regional y en la cuenca mediterránea
Efficacy and Safety of Oral Administration of a Mixture of Probiotic Strains in Patients with Psoriasis: A Randomized Controlled Clinical Trial.
The aim of this 12-week randomized, double-blind, placebo-controlled trial was to determine the efficacy and safety of a probiotic mixture in the reduction of psoriasis severity. Ninety 18-70-year-old adults with plaque psoriasis were randomized into probiotic and placebo groups. At 12-week follow-up, 66.7% of patients in the probiotic group and 41.9% in the placebo group showed a reduction in Psoriasis Area and Severity Index of up to 75% (p < 0.05). A clinically relevant difference was observed in Physician Global Assessment index: 48.9% in the probiotic group achieved a score of 0 or 1, compared with 30.2% in the placebo group. The results of follow-up 6 months after the end of the study showed a lower risk of relapse after the intake of the probiotic mixture. Analysis of gut microbiota confirmed the efficacy of the probiotic in modulation of the microbiota composition
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters.
Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs).
Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001).
Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio
Discovery of two new magnesium-bearing species in IRC+10216: MgC3N and MgC4H
10 pags., 5 figs., 7 tabs., 5 apps.We report on the detection of two series of harmonically related doublets in IRC+10216. From the observed frequencies, the rotational
constant of the first series is B = 1380.888 MHz and that of the second series is B = 1381.512 MHz. The two series correspond to
two species with a 2Σ electronic ground state. After considering all possible candidates, and based on quantum chemical calculations,
the first series is assigned to MgC3N and the second to MgC4H. For the latter species, optical spectroscopy measurements support its
identification. Unlike diatomic metal-containing molecules, the line profiles of the two new molecules indicate that they are formed in
the outer layers of the envelope, as occurs for MgNC and other polyatomic metal-cyanides. We also confirm the detection of MgCCH
that was previously reported from the observation of two doublets. The relative abundance of MgC3N with respect to MgNC is close to
one while that of MgC4H relative to MgCCH is about ten. The synthesis of these magnesium cyanides and acetylides in IRC+10216
can be explained in terms of a two-step process initiated by the radiative association of Mg+ with large cyanopolyynes and polyynes
followed by the dissociative recombination of the ionic complexes.The Spanish authors thank the Ministerio de Ciencia Innovación y Universidades for funding support from the CONSOLIDER-Ingenio
program “ASTROMOL” CSD 2009-00038, AYA2012-32032, AYA2016-75066-C2-1-P.
We also thank ERC for funding through grant ERC-2013-Syg610256-NANOCOSMOS. MA thanks the Ministerio de Ciencia Innovación y
Universidades for the Ramón y Cajal grant RyC-2014-16277. CB thanks the
Ministerio de Ciencia Innovación y Universidades for the Juan de la Cierva
grant FJCI-2016-27983. LVP acknowledges support from the Swedish Research
Council and from ERC consolidator grant 61
MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients
Anti-angiogenic therapy benefits many patients with advanced renal cell carcinoma (RCC), but there is still a need for predictive markers that help in selecting the best therapy for individual patients. MicroRNAs (miRNAs) regulate cancer cell behavior and may be attractive biomarkers for prognosis and prediction of response. Forty-four patients with RCC were recruited into this observational prospective study conducted in nine Spanish institutions. Peripheral blood samples were taken before initiation of therapy and 14 days later in patients receiving first-line therapy with sunitinib for advanced RCC. miRNA expression in peripheral blood was assessed using microarrays and L2 boosting was applied to filtered miRNA expression data. Several models predicting poor and prolonged response to sunitinib were constructed and evaluated by binary logistic regression. Blood samples from 38 patients and 287 miRNAs were evaluated. Twenty-eight miRNAs of the 287 were related to poor response and 23 of the 287 were related to prolonged response to sunitinib treatment. Predictive models identified populations with differences in the established end points. In the poor response group, median time to progression was 3.5 months and the overall survival was 8.5, whereas in the prolonged response group these values were 24 and 29.5 months, respectively. Ontology analyses pointed out to cancer-related pathways, such angiogenesis and apoptosis. miRNA expression signatures, measured in peripheral blood, may stratify patients with advanced RCC according to their response to first-line therapy with sunitinib, improving diagnostic accuracy. After proper validation, these signatures could be used to tailor therapy in this setting
The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy
<div><p>Background</p><p>Trastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. The Long-Her study was designed to identify clinical and molecular markers that could differentiate long-term survivors from patients having early progression after trastuzumab treatment.</p><p>Methods</p><p>Data were collected from women with HER2-positive metastatic breast cancer treated with trastuzumab that experienced a response or stable disease during at least 3 years. Patients having a progression in the first year of therapy with trastuzumab were used as a control. Genes related with trastuzumab resistance were identified and investigated for network and gene functional interrelation. Models predicting poor response to trastuzumab were constructed and evaluated. Finally, a mutational status analysis of selected genes was performed in HER2 positive breast cancer samples.</p><p>Results</p><p>103 patients were registered in the Long-HER study, of whom 71 had obtained a durable complete response. Median age was 58 years. Metastatic disease was diagnosed after a median of 24.7 months since primary diagnosis. Metastases were present in the liver (25%), lungs (25%), bones (23%) and soft tissues (23%), with 20% of patients having multiple locations of metastases. Median duration of response was 55 months. The molecular analysis included 35 patients from the group with complete response and 18 patients in a control poor-response group. Absence of trastuzumab as part of adjuvant therapy was the only clinical factor associated with long-term survival. Gene ontology analysis demonstrated that PI3K pathway was associated with poor response to trastuzumab-based therapy: tumours in the control group usually had four or five alterations in this pathway, whereas tumours in the Long-HER group had two alterations at most.</p><p>Conclusions</p><p>Trastuzumab may provide a substantial long-term survival benefit in a selected group of patients. Whole genome expression analysis comparing long-term survivors vs. a control group predicted early progression after trastuzumab-based therapy. Multiple alterations in genes related to the PI3K-mTOR pathway seem to be required to confer resistance to this therapy.</p></div
Supervised hierarchical clustering for all samples using 1052 differentially expressed probesets identified using SAM.
<p>Each row represents a probeset and each column a sample. Green bars indicate samples from patients in Long-HER group, red bars indicate samples from short-term responders. There are two samples duplicated, * account for metastasis samples.</p
Signaling pathway annotation enrichment analysis for 858 genes related with trastuzumab resistance.
<p>This analysis was performed using SPEED software. PI3K pathway appeared as the most relevant pathway in relation with trastuzumab resistance.</p